名媛直播

In this exclusive 名媛直播 video, , of City of Hope in Duarte, California, discusses some of the high points of his presentation at the recent American Society of Clinical Oncology (ASCO) meeting, titled "What is variant histology renal cell cancer and what are the available treatment options?"

The following is a transcript of his remarks:

So this year at ASCO, I gave a presentation around non-clear cell kidney cancer. Now this is really a loaded term. It represents 15% of kidney cancer cases, but in fact, it's really a spectrum of different diseases.

Most common subtype of non-clear cell kidney cancer is papillary renal cell carcinoma. So I talked a lot about the current treatment approaches. I led a large randomized study called the PAPMET study that was published in a couple of years ago that I think has really set the stage to prove that we can do randomized trials. But it was a randomized phase II. I would say that the standard for papillary kidney cancer is still not set. So we really have a lot of work to be done.

I presented some of the compelling data for combinations of cabozantinib [Cabometyx] and other TKIs [tyrosine kinase inhibitors] with immunotherapy, and I also presented some of the rationale for some of the phase III clinical trials that are looking at TKI with immunotherapy versus, for instance, TKIs that are being done in papillary that I think will really set the stage for the disease.

I also focused on my presentation on the smaller but very important datasets around the very rare histologies like chromophobe kidney cancer, collecting duct kidney cancer and renal medullary cancer. These are really exquisitely rare diseases, but what I think is so beautiful is that our investigative communities really proved that we can do studies in these spaces.

In the last part of my talk, I really focused on the patient advocate and their role in all of this because I do think that they're essential in terms of linking the patients to clinical trials, and that's something that we need to do in order to move the field of non-clear cell kidney cancer forward. So I'd interviewed a number of patient advocates. Their comments are incorporated in my presentation, and it really was a great opportunity to get their critical perspective on how to move the field forward.

Comment